Please ensure Javascript is enabled for purposes of website accessibility

Why You Should Own Biotech Stocks Now

By Taylor Carmichael - Updated Mar 12, 2021 at 9:40AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The confluence of healthcare and technology will send many biotech stocks soaring over the next decade.

What is biotech and why do you want to own shares of biotech stocks? Corinne Cardina, bureau chief of healthcare and cannabis at Fool.com, and Motley Fool contributor Taylor Carmichael define the biotech universe and discuss why you want to invest here. This segment was recorded live on March 5.

Corinne Cardina: Taylor, could you share one thing that investors should know about biotechs and what are their defining characteristics and we'll try to keep it brief so we can start talking about some names.

Taylor Carmichael: Well, to me biotech, what it really is, is technology, it's bringing technology to healthcare and so you think of a company like Moderna (MRNA 2.81%) or BioNTech (BNTX 1.38%) that had this mRNA platform. It's a new form of technology so it enables them to discover drugs quicker so that's the quintessential biotech kind of transition, that you have a new platform, a new form of technology. We've had drug discovery for a long time, but it's getting much more specific and quicker, faster, better. It's improving and we've had biotechs for, I don't know, since Amgen (AMGN 0.71%), I guess, 30 or 40 years. But the real kind of big event in terms of the biotech industry, I think, is sequencing the DNA, the human DNA and that has opened the door to a lot more knowledge and a lot more investing in terms of knowing more, giving drug researchers a map of the human body and being able to say, OK, this is what we want to target. This is what we want to do and we're getting more and more, you are seeing more and more of the kind of the interconnection of technology and tech stocks and healthcare and so you're seeing, you see that with Illumina (ILMN 0.15%), you see with Microsoft running the computers for Adaptive Biotechnologies (ADPT 1.30%). I mean, you just see a lot of high-tech stuff using computers, using artificial intelligence, supplying drug candidates. So that's all a part of biotech now.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$249.26 (0.71%) $1.76
Microsoft Corporation Stock Quote
Microsoft Corporation
MSFT
$260.87 (3.29%) $8.31
Illumina, Inc. Stock Quote
Illumina, Inc.
ILMN
$243.86 (0.15%) $0.37
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$140.08 (2.81%) $3.83
Adaptive Biotechnologies Corporation Stock Quote
Adaptive Biotechnologies Corporation
ADPT
$7.81 (1.30%) $0.10
BioNTech SE Stock Quote
BioNTech SE
BNTX
$165.25 (1.38%) $2.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.